Peptic ulcer disease is the presence of ulceration in the stomach and proximal duodenum commonly and in the lower esophagus, distal duodenum or jejunum infrequently. It is characterized by mucosal damage secondary to pepsin and gastric acid secretion.
It is the principal cause of upper gastrointestinal hemorrhage.
Appropriate therapy depends on the cause of peptic ulcer disease.
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
Recurrent bleeding rates among patients with a history of Helicobacter pylori-negative idiopathic ulcer bleeding are low and do not significantly differ between users of the proton pump inhibitor lansoprazole and the histamine 2 receptor antagonist famotidine, according to the results of an industry-independent trial.
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Vonoprazan is as effective as the proton pump inhibitor (PPI) lansoprazole for preventing peptic ulcer recurrence in patients receiving low-dose aspirin (LDA) therapy for cardiovascular or cerebrovascular protection, as shown in a phase III study. In addition, the drug appears to be well tolerated, with its preventive effect enduring with long-term use.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Gastroenterology - Malaysia digital copy today!
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.